/OGN
OGN Stock - Organon & Co.
Healthcare|Drug Manufacturers - GeneralNYSE
$6.83-0.07%
$0.01 (-0.07%) • Dec 19
41
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).33
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-8.5%upside
Target: $6.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.76 – $6.90
TARGET (TP)$6.25
STOP LOSS$6.28
RISK/REWARD1:-1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.54
52W High$17.23
52W Low$6.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.40B | $6.26B | $6.17B | $6.30B | $6.53B |
| Gross Profit | $3.71B | $3.75B | $3.88B | $3.92B | $4.41B |
| Gross Margin | 58.0% | 59.8% | 62.8% | 62.2% | 67.6% |
| Operating Income | $1.49B | $1.33B | $1.71B | $1.92B | $2.85B |
| Net Income | $864.00M | $1.02B | $917.00M | $1.35B | $2.16B |
| Net Margin | 13.5% | 16.3% | 14.9% | 21.4% | 33.1% |
| EPS | $3.36 | $4.01 | $3.61 | $5.33 | $8.52 |
Company Overview
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
2
40%
Sell / Underperform
1
20%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$25
Average Target
↑ 259.4% Upside
Now
$5
Low
$25
Average
$40
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Underweight | $7.5 |
| October 27th 2025 | Piper Sandler | Downgrade | Underweight | $5 |
| May 2nd 2025 | Evercore ISI | Downgrade | In-line | - |
| September 6th 2024 | JP Morgan | Downgrade | Underweight | $20← $18 |
| November 3rd 2023 | Goldman | Downgrade | Neutral | $16← $33 |
| September 21st 2023 | Barclays | Initiation | Overweight | $28 |
| March 16th 2023 | Raymond James | Initiation | Outperform | $33 |
| October 14th 2022 | BofA Securities | Downgrade | Underperform | $25← $27 |
| September 6th 2022 | Piper Sandler | Upgrade | Overweight | $34← $37 |
| August 5th 2022 | BofA Securities | Downgrade | Neutral | $37← $40 |
| April 27th 2022 | Goldman | Initiation | Buy | $40 |
Earnings History & Surprises
OGNBeat Rate
72%
Last 18 quarters
Avg Surprise
+9.6%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$1.01
Q4 2025
EPS Surprise History
Q1 24
+10.0%
$0.88vs$0.80
Q2 24
+25.8%
$1.22vs$0.97
Q3 24
+5.7%
$1.12vs$1.06
Q4 24
-3.3%
$0.87vs$0.90
Q1 25
-2.2%
$0.90vs$0.92
Q2 25
+14.6%
$1.02vs$0.89
Q3 25
+6.4%
$1.00vs$0.94
Q4 25
+8.6%
$1.01vs$0.93
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $0.74 | — | — | — |
Q4 2025 | Nov 10, 2025 | $0.93 | $1.01 | +8.6% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.94 | $1.00 | +6.4% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.89 | $1.02 | +14.6% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $0.92 | $0.90 | -2.2% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $0.90 | $0.87 | -3.3% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $1.06 | $1.12 | +5.7% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $0.97 | $1.22 | +25.8% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $0.80 | $0.88 | +10.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $1.04 | $0.87 | -16.3% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $0.97 | $1.31 | +35.1% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $1.18 | $1.08 | -8.5% | ✗ MISS |
Q1 2023 | Feb 16, 2023 | $0.85 | $0.81 | -4.7% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $1.12 | $1.32 | +17.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $1.16 | $1.25 | +7.8% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $1.30 | $1.65 | +26.9% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $1.25 | $1.37 | +9.6% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $1.44 | $1.67 | +16.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $1.40 | $1.72 | +22.9% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On Organon with Underweight Rating, Announces Price Target of $7.5
📉 NegativeBenzinga•Dec 9, 2025, 03:09 PM•Also:
The FDA Has Approved Shanghai Henlius Biotech And Organon's Partnered Biologics License Application For Poherdy, An Interchangeable Biosimilar To Perjeta (Pertuzumab), For All Indications Of The Reference Product
📈 PositiveBenzinga•Nov 17, 2025, 10:32 AM
JP Morgan Maintains Underweight on Organon, Lowers Price Target to $12
📉 NegativeBenzinga•Nov 11, 2025, 04:10 PM
Morgan Stanley Maintains Equal-Weight on Organon, Lowers Price Target to $9
📉 NegativeBenzinga•Nov 11, 2025, 12:35 PM
Organon shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 10, 2025, 04:53 PM
Organon Lowers FY2025 Sales Guidance from $6.275B-$6.375B to $6.200B-$6.250B vs $6.289B Est
📉 NegativeBenzinga•Nov 10, 2025, 12:32 PM
Organon Q3 Adj. EPS $1.01 Beats $0.94 Estimate, Sales $1.602B Beat $1.575B Estimate
📈 PositiveBenzinga•Nov 10, 2025, 12:31 PM
Reported Saturday, Organon Phase 3 ADORING Trials Demonstrate VTAMA Cream Achieves Rapid Skin Clearance And Itch Relief In Pediatric Atopic Dermatitis With Or Without Comorbidities
📈 PositiveBenzinga•Nov 10, 2025, 09:27 AM
Organon To Divest Its JADA System To Laborie Medical Technologies For Up To $465M
📈 PositiveBenzinga•Nov 7, 2025, 12:32 PM
Organon cut to Underweight at Piper Sandler on internal control concerns
📉 NegativeSeeking Alpha•Oct 27, 2025, 03:27 PM
Organon shares are trading lower after CEO Kevin Ali resigned in connection with an Audit Committee investigation; Joseph Morrissey appointed Interim CEO.
📉 NegativeBenzinga•Oct 27, 2025, 01:47 PM
Organon names interim CEO after internal probe uncovers improper wholesaler sales practices
📉 NegativeSeeking Alpha•Oct 27, 2025, 11:49 AM
Organon Board Appoints EVP And Head Of Manufacturing & Supply, Joseph Morrissey, As Interim CEO, Following Kevin Ali Resignation
➖ NeutralBenzinga•Oct 27, 2025, 11:38 AM
Deputy Director Of The White House Domestic Policy Council Says New Fertility Benefit Option For Employers To Offer To Employees
📈 PositiveBenzinga•Oct 16, 2025, 08:13 PM•Also: , ,
President Trump Says EMD Serono Will Largely Bring Back Production To The United States; Cost Of Per Cycle Will Fall By 73%; We Will Take Steps To Vastly Expand Coverage Of Fertility; Americans Will Be Able To Opt In To Specialized Coverage For Fertility
📈 PositiveBenzinga•Oct 16, 2025, 07:56 PM•Also: , ,
President Trump Says We Will Dramatically Slash Cost Of IVF; I Am Pleased To Announced EMD Serono Has Agreed To Provide Massive Discounts On Fertility Drugs Sold In The U.S.; EMD Serono Agrees That All Future Drugs Will Be Offset At Most Favored Nation Prices
➖ NeutralBenzinga•Oct 16, 2025, 07:52 PM•Also: , ,
'White House Set To Announce Proposal Seeking To Make I.V.F. More Accessible' - NY Times
➖ NeutralBenzinga•Oct 16, 2025, 04:53 PM•Also: , ,
Henlius And Organon Secure European Commission Approval For BILDYOS And BILPREVDA Denosumab Biosimilars To Prolia And Xgeva Covering All Indications Across EU
📈 PositiveBenzinga•Sep 19, 2025, 10:03 AM
FDA Approves Henlius And Organon's BILDYOS And BILPREVDA, Biosimilars To Amgen's PROLIA And XGEVA, Expanding US Bone Health Treatment Options
📈 PositiveBenzinga•Sep 2, 2025, 09:37 AM•Also:
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus
📈 PositiveSeeking Alpha•Aug 5, 2025, 12:18 PM
Frequently Asked Questions about OGN
What is OGN's current stock price?
Organon & Co. (OGN) is currently trading at $6.83 per share. The stock has moved -0.07% today.
What is the analyst price target for OGN?
The average analyst price target for OGN is $6.25, based on 1 analyst.
What sector is Organon & Co. in?
Organon & Co. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is OGN's market cap?
Organon & Co. has a market capitalization of $1.78 billion, making it a small-cap company.
Does OGN pay dividends?
No, Organon & Co. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVO
Alvotech
$4.90
Mkt Cap: $1.5B
AUPH
Aurinia Pharmaceuticals Inc.
$16.18
Mkt Cap: $2.1B
AVDL
Avadel Pharmaceuticals plc
$21.47
Mkt Cap: $2.1B
GRDN
Guardian Pharmacy Services, Inc.
$31.54
Mkt Cap: $2.0B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
MD
Pediatrix Medical Group, Inc.
$21.91
Mkt Cap: $1.9B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
PAHC
Phibro Animal Health Corporation
$37.25
Mkt Cap: $1.5B
SEM
Select Medical Holdings Corporation
$15.01
Mkt Cap: $1.9B
TLRY
Tilray Brands, Inc.
$11.16
Mkt Cap: $1.2B
Explore stocks similar to OGN for comparison